Tezepelumab Helps Severe Asthma Patients Reduce Oral Steroids over 28 Weeks

Why It Matters

Reducing oral steroid exposure mitigates serious side effects and improves quality of life, positioning tezepelumab as a game‑changer in severe asthma management and a potential cost‑saver for healthcare systems.

Key Takeaways

• Tezepelumab cut oral steroid dose by ≥50% in 69% of patients.
• Placebo group achieved same reduction in only 44% of participants.
• 35% on tezepelumab stopped steroids entirely vs 21% on placebo.
• Reduced steroid use lowers risk of diabetes, osteoporosis, cardiovascular disease.
• SUNRISE Phase III trial confirms efficacy and safety for severe asthma.

Pulse Analysis

Severe asthma remains a major public health challenge, affecting roughly 5% of the adult population and often requiring daily oral corticosteroids (OCS) to control symptoms. While OCS can stabilize airway inflammation, chronic use is linked to diabetes, osteoporosis, cardiovascular disease, and diminished quality of life, driving a pressing need for steroid‑sparing therapies. Biologic agents targeting specific inflammatory pathways have emerged, yet few have demonstrated robust reductions in OCS dependence without compromising asthma control.

The SUNRISE Phase III trial enrolled adults with OCS‑dependent severe asthma across multiple centers, randomizing them to tezepelumab or placebo for 28 weeks. Results were striking: 69% of the tezepelumab group achieved at least a 50% reduction in OCS dose, and more than one‑third discontinued steroids altogether. By contrast, the placebo arm lagged behind, with only 44% reaching the 50% reduction threshold and 21% stopping OCS. Importantly, lung function and exacerbation rates remained stable, underscoring that the steroid taper did not erode disease control. Compared with other biologics such as dupilumab or mepolizumab, tezepelumab’s upstream inhibition of thymic stromal lymphopoietin appears to deliver broader anti‑inflammatory effects, translating into superior steroid‑sparing outcomes.

For clinicians, payers, and patients, these data signal a paradigm shift. Tezepelumab offers a pathway to reduce long‑term OCS exposure, potentially lowering associated comorbidities and healthcare costs. The trial’s safety profile further supports its integration into treatment algorithms for OCS‑dependent asthma. As the drug moves toward broader regulatory approval, real‑world studies will be essential to confirm durability of steroid reduction and to assess cost‑effectiveness in diverse patient populations. The SUNRISE findings thus set the stage for a new standard of care that prioritizes both efficacy and safety in severe asthma management.